Your browser doesn't support javascript.
loading
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
Weintraub, William S; Bhatt, Deepak L; Zhang, Zugui; Dolman, Sarahfaye; Boden, William E; Bress, Adam P; King, Jordan B; Bellows, Brandon K; Tajeu, Gabriel S; Derington, Catherine G; Johnson, Jonathan; Andrade, Katherine; Steg, P Gabriel; Miller, Michael; Brinton, Eliot A; Jacobson, Terry A; Tardif, Jean-Claude; Ballantyne, Christie M; Kolm, Paul.
Afiliación
  • Weintraub WS; MedStar Healthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC.
  • Bhatt DL; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts.
  • Zhang Z; Institute for Research on Equity and Community Health, ChristianaCare Health System, Newark, Delaware.
  • Dolman S; MedStar Healthcare Delivery Research Network, MedStar Health Research Institute, Washington, DC.
  • Boden WE; Department of Medicine, Cardiology Section, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.
  • Bress AP; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
  • King JB; Department of Population Health Sciences, University of Utah, Salt Lake City.
  • Bellows BK; Department of Population Health Sciences, University of Utah, Salt Lake City.
  • Tajeu GS; Department of Medicine, Columbia University, New York, New York.
  • Derington CG; Health Services Administration and Policy, Temple University, Philadelphia, Pennsylvania.
  • Johnson J; Department of Population Health Sciences, University of Utah, Salt Lake City.
  • Andrade K; Health Economics and Outcomes Research, Optum, Eden Prairie, Minnesota.
  • Steg PG; Health Economics and Outcomes Research, Optum, Eden Prairie, Minnesota.
  • Miller M; Medical School of Université de Paris, Paris, France.
  • Brinton EA; Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • Jacobson TA; French Alliance for Cardiovascular Trials (FACT), INSERM U-1148, Paris, France.
  • Tardif JC; Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Ballantyne CM; Utah Lipid Center, Salt Lake City.
  • Kolm P; Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University, Atlanta, Georgia.
JAMA Netw Open ; 5(2): e2148172, 2022 02 01.
Article en En | MEDLINE | ID: mdl-35157055
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Eicosapentaenoico / Análisis Costo-Beneficio / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hiperlipidemias Tipo de estudio: Clinical_trials / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Netw Open Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Eicosapentaenoico / Análisis Costo-Beneficio / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Hiperlipidemias Tipo de estudio: Clinical_trials / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Netw Open Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos